Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FF EAI Robotics Ecosystem Inc.QLGN · Entity 7776 | Director | July 11, 2022 | August 04, 2022 |
| LIFECORE BIOMEDICAL, INC. \DE\LFCR · Entity 6447 | Director | June 04, 2026 | June 05, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | President & COO | September 20, 2024 | September 24, 2024 |
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | CFO, Treasurer | June 12, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FF EAI Robotics Ecosystem Inc.
Report date July 11, 2022 · Filed August 04, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.51 · Expires 2032-07-11 | Direct | 40,000 |
Reported balance
After 2022-07-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-11 · Grant · Acquired 40,000 · Balance 40,000 F1: Shares underlying the stock option vest over three years in equal annual installments from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares underlying the stock option vest over three years in equal annual installments from the date of grant.
LIFECORE BIOMEDICAL, INC. \DE\
Report date June 04, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 69,967 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 25,907 · Balance 69,967 F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis. F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026). |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2: Vests on earlier of June 4, 2027 or the date of the annual meeting of stockholders of the Company first held in calendar year 2027 (provided such date is no less than 50 weeks from June 4, 2026).
LIGAND PHARMACEUTICALS INC
Report date September 20, 2024 · Filed September 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,777 |
Ending reported balance
After 2024-09-23 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2024-09-20 · Exercise / conversion · Acquired 4,982 · Balance 57,052 Row 2 · 2024-09-20 · Sale · Disposed 6,275 · Balance 50,777 F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2024-09-23 · Exercise / conversion · Acquired 395 · Balance 51,172 Row 4 · 2024-09-23 · Exercise / conversion · Acquired 9,377 · Balance 60,549 Row 5 · 2024-09-23 · Sale · Disposed 2,481 · Balance 58,068 F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2024-09-23 · Sale · Disposed 7,090 · Balance 50,978 F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2024-09-23 · Sale · Disposed 201 · Balance 50,777 F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.99 · Expires 2026-02-11 | Direct | 395 |
Reported balance
After 2024-09-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-09-20 · Exercise / conversion · Disposed 4,982 · Balance 395 F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.99 · Expires 2026-02-11 | Direct | 0 |
Reported balance
After 2024-09-23 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-09-23 · Exercise / conversion · Disposed 395 · Balance 0 F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $52.84 · Expires 2032-05-05 | Direct | 42,436 |
Reported balance
After 2024-09-23 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-09-23 · Exercise / conversion · Disposed 9,377 · Balance 42,436 F6: This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
F6: This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026.
PALVELLA THERAPEUTICS, INC.
Report date June 12, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,000 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Exercise / conversion · Acquired 1,000 · Balance 1,000 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60 · Expires 2034-12-13 | Direct | 166,100 |
Reported balance
After 2026-06-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-12 · Exercise / conversion · Disposed 1,000 · Balance 166,100 F1: 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the stock options will vest on October 16, 2025, and the remaining 75% will vest in equal monthly tranches over the following 36 months.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2018 Filed Aug 7, 2018 20:35 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 836 | $226.74 | $189,554.64 |
DisclosureSEC source: 0000886163-18-000111 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,559 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 08/06/2015. Read SEC document |
| June 29, 2018 Filed Jul 3, 2018 19:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 180 | $117.84 | $21,210.39 |
DisclosureSEC source: 0000886163-18-000089 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,395 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 550 | $165.87 | $91,228.50 |
DisclosureSEC source: 0000886163-18-000038 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,215 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| March 06, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,004 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000038 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,765 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/11/2016 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the two-year performance period ending December 31, 2017. On March 05, 2018, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 16,050 | $0.00 Strike: $159.01 | $0.00 |
DisclosureSEC source: 0000886163-18-000038 · edgardoc.xml · derivative · entry 4 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,050 Underlying: Common Stock · 16,050 shares Expires 2028-03-02 F3 · derivative.exercise_date: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exerciseable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant is 03/02/18. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 23:36 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,074 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-18-000038 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,761 Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 326 | $157.18 | $51,240.68 |
DisclosureSEC source: 0000886163-18-000016 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,687 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/24/2017. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 22:37 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 354 | $157.18 | $55,641.72 |
DisclosureSEC source: 0000886163-18-000016 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · EVP,Finance & Strategy and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,013 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| December 28, 2017 Filed Dec 30, 2017 02:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,530 | $138.66 | $212,149.80 |
DisclosureSEC source: 0000886163-17-000160 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,367 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| December 28, 2017 Filed Dec 30, 2017 02:17 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000160 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,897 F1 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/10/2015 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the three-year performance period ending December 31, 2017. On December 28, 2017, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| November 17, 2017 Filed Nov 17, 2017 22:11 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 6,559 | $142.63 | $935,510.17 |
DisclosureSEC source: 0000886163-17-000137 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,147 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.51 to $144.16, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2017 Filed Aug 8, 2017 21:50 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 609 | $122.06 | $74,334.54 |
DisclosureSEC source: 0000886163-17-000093 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,706 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 08/06/2015. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 22:44 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 243 | $87.13 | $21,171.38 |
DisclosureSEC source: 0000886163-17-000084 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,315 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 15,225 | $0.00 Strike: $100.38 | $0.00 |
DisclosureSEC source: 0000886163-17-000030 · edgardoc.xml · derivative · entry 6 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,225 Underlying: Common Stock · 15,225 shares Expires 2027-02-24 F5 · derivative.exercise_date: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Optioned Shares per month thereafter. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,567 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000030 · edgardoc.xml · nonDerivative · entry 5 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,072 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 1,051 | $100.38 | $105,499.38 |
DisclosureSEC source: 0000886163-17-000030 · edgardoc.xml · nonDerivative · entry 4 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,505 F4 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 3,450 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-17-000030 · edgardoc.xml · nonDerivative · entry 3 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,556 F3 · shares: Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer?s common stock. The PSUs were originally granted on 02/10/2015 and were eligible to vest based on the Issuer?s achievement of certain performance objectives during the two-year performance period ending December 31, 2016. On February 24, 2017, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer?s achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares. Read SEC document |
| February 15, 2017 Filed Feb 28, 2017 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 391 | $104.28 | $40,773.48 |
DisclosureSEC source: 0000886163-17-000030 · edgardoc.xml · nonDerivative · entry 2 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,106 F2 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2016. Read SEC document |
| December 30, 2016 Filed Jan 3, 2017 21:38 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | OtherCommon Stock | 40 | $86.37 | $3,454.74 |
DisclosureSEC source: 0000886163-17-000003 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,106 F1 · kind: Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c). Read SEC document |
| August 06, 2016 Filed Feb 28, 2017 23:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 609 | $123.30 | $75,089.70 |
DisclosureSEC source: 0000886163-17-000030 · edgardoc.xml · nonDerivative · entry 1 Korenberg Matthew E · CIK 0001649903 · VP, Finance and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,457 F1 · shares: Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 08/06/2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.